CureVac NV

CureVac NV, incorporated in the year 2000, is a biopharmaceutical company with its headquarters located in Tübingen, Germany. The company also operates additional sites in Frankfurt, Germany, and Boston, MA, USA. CureVac NV is primarily engaged in the development of mRNA-based vaccines and therapies, with activities spanning several key business segments. The company's most important business categories include prophylactic vaccines, which focus on the prevention of infectious diseases; therapeutic vaccines, which are being created for the treatment of various diseases with a particular emphasis on oncology; and mRNA-based therapies, aimed at treating rare diseases or for enabling protein production. Although CureVac NV is not associated with conventional consumer brands, it is well-known for its work in mRNA technology. Its most publicized product is the mRNA-based COVID-19 vaccine candidate, referred to as CVnCoV or CvnCoV. CureVac NV conducts research and development primarily in Germany and the United States. The global nature of biopharmaceutical development suggests that upon achieving regulatory approval and successful commercialization, CureVac NV's products would be sold in various markets worldwide. The reach of the company's vaccine candidate, particularly during the COVID-19 pandemic, was anticipated to be significant, though the market reach of the specific COVID-19 vaccine by CureVac NV may have been affected by comparative effectiveness to others on the market as of the latest available information. (Powered by AI)